C17orf50: A Promising Drug Target and Potential Biomarker for Cancer Treatment

Target Name: C17orf50

NCBI ID: G146853

C17orf50

Other Name(s): Uncharacterized protein C17orf50 | CQ050_HUMAN | Chromosome 17 open reading frame 50 | chromosome 17 open reading frame 50

C17orf50: A Promising Drug Target and Potential Biomarker for Cancer Treatment

Abstract:
C17orf50 is a highly conserved protein located in the C17 region of human chromosome 17. Despite its simple structure, C17orf50 has been implicated in numerous cellular processes, including cell adhesion, migration, and invasion. Recent studies indicate that C17orf50 may have the potential to become a drug target. points (or biomarkers), particularly in cancer treatment. This article will elaborate on the structure, function, role of C17orf50 in tumorigenesis and its possibility as a drug target, and explore the application prospects of C17orf50 in cancer treatment.

Introduction:
C17orf50, whose scientific name is human chorionic gonadotropin (hCG)伪-like transcription factor-50, is a conserved, highly complex protein located in the C17 region of human chromosome 17. It plays an important role in a variety of physiological processes, including cell adhesion, cell migration, and tumor invasion. Abnormal expression of C17orf50 is closely related to the onset and development of various cancers. Therefore, studying the application prospects of C17orf50 in cancer treatment has important clinical significance.

Structure and Function:
C17orf50 consists of 174 amino acids and its molecular weight is 21.9 kDa. Similar to other transcription factors, C17orf50 has 伪-helix, 尾-sheet and a certain degree of rod-like structure. The DNA-binding domain of C17orf50 consists of a core 伪-helix, a free 尾-segment, and a hydrogen-bonding 伪-helix. In addition, the C-terminus of C17orf50 is rich in cysteine, which may be an important conserved amino acid related to function.

In cell biology, C17orf50 plays a key role in a variety of physiological processes. It plays a role in cell adhesion, cell migration and tumor invasion. Studies have shown that C17orf50 is up-regulated in a variety of tumors and is positively correlated with tumor invasion, growth and metastasis capabilities. In addition, C17orf50 also has important functions in embryonic development, such as determining the differentiation of germ cells.

Drug Target and Potential Biomarker:
The conserved structure, multiple physiological functions, and association with tumor development and progression of C17orf50 make it a potential drug target. Further research will determine the role of C17orf50 in cancer treatment, including as a drug target, biomarker or drug intervention target.

Application prospects:
As a drug target, C17orf50 has broad application prospects in cancer treatment. Drug intervention targeting C17orf50 can inhibit the growth of tumor cells, increase the sensitivity of tumor cells to drugs, and improve the survival rate of tumor patients. The role of C17orf50 in tumorigenesis makes it an important biomarker for cancer diagnosis, prognosis and treatment.

Conclusion:
C17orf50 is a significantly conserved protein that plays an important role in a variety of physiological processes. In cancer treatment, abnormal expression of C17orf50 is closely related to tumor occurrence, development and treatment response. Drug intervention targeting C17orf50 is expected to bring better therapeutic effects and quality of life to cancer patients. In the future, C17orf50 is expected to become an important drug target or biomarker in cancer treatment.

Protein Name: Chromosome 17 Open Reading Frame 50

The "C17orf50 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C17orf50 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets